Optimal usage of radium-223 in metastatic castration-resistant prostate cancer

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer

Radium-223 is a first-in-class α-emitting radiopharmaceutical that targets bone metastases associated with metastatic castration-resistant prostate cancer (mCRPC). In the pivotal phase III trial ALSYMPCA, radium-223 significantly increased overall survival (OS), compared with placebo (median 14.9 vs...

Full description

Bibliographic Details
Main Authors: Tai-Lung Cha, Tony Tong-Lin Wu, Nicholas John Vogelzang, Chao-Yuan Huang, Shu-Pin Huang, Chia-Chi Lin, Yen-Chuan Ou, See-Tong Pang, Daniel Heung-Yuan Shen, Wen-Jeng Wu, Wayne Yen-Hwa Chang
Format: Article
Language:English
Published: Elsevier 2017-11-01
Series:Journal of the Formosan Medical Association
Subjects:
Radium chloride Ra 223
Radiopharmaceuticals
Castration-resistant prostate cancer
Osteoblasts
Online Access:http://www.sciencedirect.com/science/article/pii/S0929664616302492

Internet

http://www.sciencedirect.com/science/article/pii/S0929664616302492

Similar Items